Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen has extended its partnership with Chroma Therapeutics. As a part of this partnership, Invitrogen will use its SelectScreen platform to perform biochemical screening on Chroma's multi-targeted kinase inhibitors at Invitrogen's Paisley, Scotland, UK, facility.
Subscribe to our email newsletter
Invitrogen’s SelectScreen profiling and screening service integrates enzyme collections and cell-lines with state-of-the-art bioassay technologies to accelerate drug discovery programs.
Alan Drummond, chief scientific officer of Chroma, said: “Invitrogen’s large panel of kinases allows us to determine whether our candidate drugs are inhibiting the appropriate kinases and how they interact with other kinases, enabling us to predict potential side effects or new indications.”